The nanobiomaterials and biotechnology may define a new future in personalised medicine. However, there is a lack of robust preclinical evidence on toxicity of nanobiomaterials and complex regulatory issues, being imperative to properly address the safety aspects regarding the toxicological impact to human health.
RESTORE is addressing the complex regulatory issues and access nanobiomaterials toxicity impact to human health, by working closely with regulatory authorities to ensure a targeted and efficient product development. Strict safety and regulatory aspects is being emphasised in all steps of the project, ensuring that all relevant safety procedures are carried following adequate protocols and respecting all ethical related issues.